Page 1

September 27 , 2021 E dermata Dermata Therapeutics , Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Completed oversubscribed $ 18 million Initial Public Offering ( IPO ) - - Set to announce topline results from its DMT310 Phase 1b proof of concept ( POC ) study in mild to moderate psoriasis in 4Q 2021 - - On track to initiate DMT310 Phase 2 study for moderate to severe rosacea in 4Q 2021 SAN DIEGO , CA / ACCESSWIRE / September 27 , 2021 / Dermata Therapeutics , Inc. ( Nasdaq : DRMA ) ( " Dermata " or the " Company " ) , a clinical - stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions , today reported financial results for the second quarter ended June 30 , 2021 and highlighted recent corporate progress . " Following the successful completion of our Nasdaq IPO , and the strengthening of our executive team and Board of Directors , we are eager to enter this next phase of Dermata's development , as we further progress our clinical pipeline , " stated Gerry Proehl , Dermata's Chairman , President and Chief Executive Officer . " We are excited with our results to date and look forward to the anticipated announcement of topline data from our DMT310 and DMT410 trials in the fourth quarter of 2021. Both of these product candidates leverage our unique Spongilla technology , and we believe represent potentially new , differentiated , and convenient treatment options to several underserved patient populations . " Corporate Highlights • Completed Oversubscribed IPO on Nasdaq . On August 17 , 2021 , Dermata completed its oversubscribed IPO issuing 2,571,428 shares of common stock and accompanying warrants to purchase up to 2,571,428 shares of common stock , which included the full exercise by the underwriters of their option to purchase 385,714 additional warrants . Gross proceeds to the Company were approximately $ 18.0 million , before deducting underwriting discounts and offering expenses . • Expanded Board of Directors . Subsequent to the successful completion of the Company's IPO , Dermata appointed four experienced life science leaders to its Board of Directors , including Steven Mento , Ph.D. , Mary Fisher , Kathleen Scott , and Andrew Sandler , M.D. , joining Gerry Proehl , David Hale , and Wendell Wierenga , Ph.D. • Expanded Executive Team . On September 1 , 2021 , Dermata appointed Kyri Van Hoose as Chief Financial Officer . Ms. Van Hoose is a strategic and operational finance leader with over 20 years of experience , including more than 15 years in the life sciences industry . • Announced Upcoming DMT410 Presentation at the American Society for